Assay enhances and simplifies M-proteins screening
Answers from the Lab
In this test-specific episode of the "Answers From the Lab" podcast, David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' new MASS-FIX Quantitation assay offers higher specificity for quantitating m-proteins in the blood, which are associated with multiple myeloma and other diseases. The new MASS-FIX Quantitative assay further enhances the MASS-FIX mass spectrometry method developed at Mayo Clinic, of which greatly improved screening for M-proteins.
The new assay (test code: QMPSS) provides greater specificity and the ease of ordering the right test at the right time for patients, for diagnostic or monitoring purposes.
"With Quantitative MASS-FIX, we're now able to achieve a significantly more specific level of quantitation than we had for SPEP," Dr. Murray says. "This new method is going to replace the traditional SPEP and immunofixation, so only one test will need to be ordered."
The new assay, QMPSS, is the fruit of five years of laboratory work, including building unique software to perform the quantitation. "Our new assay brings in more sensitivity and specificity. This is going to change the way patients are treated," Dr. Murray says.
Listen to learn more about Mayo Clinic Laboratories' MASS-FIX Quantitation assay.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.